
Cingulate (CING) Stock Forecast & Price Target
Cingulate (CING) Analyst Ratings
Bulls say
Cingulate Inc. operates within a growing market for ADHD medications, which has experienced approximately 8% annual growth since 2010, culminating in sales of nearly $18 billion in 2020. The company has reported positive topline results from its CTx-1301 trials, showing a beneficial effect compared to the placebo group, which bolsters confidence in the efficacy of its product pipeline. Given this positive trial data and the expanding market potential, there exists significant upside for Cingulate’s stock, reflecting a favorable outlook amidst high risks.
Bears say
Cingulate Inc reported a net loss of $4.8 million or an EPS of $(1.09), which was worse than both its estimates and consensus expectations, highlighting ongoing financial difficulties. Additionally, a significant net loss of $7.3 million or an EPS of $(1.35) further underscores inefficiencies, with projected estimates also falling short of expectations. The company faces multiple risks including liquidity issues, potential failure of its product candidates in clinical trials, and challenges in gaining regulatory approvals, which collectively contribute to a negative outlook on its stock performance.
This aggregate rating is based on analysts' research of Cingulate and is not a guaranteed prediction by Public.com or investment advice.
Cingulate (CING) Analyst Forecast & Price Prediction
Start investing in Cingulate (CING)
Order type
Buy in
Order amount
Est. shares
0 shares